Azurity Pharmaceuticals is cutting 75 employees effective Sept. 12 through Dec. 31 in Wilmington, Massachusetts, according to a Worker Adjustment and Retraining Notification (WARN) Act notice. The specialty pharma company’s website lists that location as a manufacturing and operating facility.
All entries for: Gastrointestinal
July 14, 2025
Azurity Pharmaceuticals
Layoffs
Wilmington, MA
501-1,000 employees
Disease Area: Cardiology, Gastrointestinal, Multiple, Neurological Diseases
Drug Type: Small Molecule
May 25, 2025
AnaptysBio
Neutral Outlook
San Diego, CA
51-200 employees
Thus, it is unclear how the IRA will be implemented but it will likely have a significant impact on the pharmaceutical industry and the pricing of our products and product candidates.
Disease Area: Dermatology, Gastrointestinal, Immune Diseases, Multiple, Oncology
Drug Type: Biologic
May 14, 2025
CalciMedica
Neutral Outlook
La Jolla, CA
1-50 employees
For example, the Inflation Reduction Act (IRA) passed by Congress authorizes the Secretary of the Department of HHS to negotiate prices directly with participating manufacturers for selected medicines covered by Medicare even if these medicines are protected by an existing patent. For small molecule medicines, the process begins seven years after initial approval by the FDA. While we do not believe that the IRA or its effects will impact our ability to obtain patents in the near future, we cannot be certain whether it will affect our patent strategy in the long run.
Disease Area: Chronic Disease, Gastrointestinal, Immune Diseases, Multiple, Respiratory Diseases
Drug Type: Biologic, Small Molecule
May 8, 2025
Third Harmonic Bio
Company Closure
San Francisco, CA
1-50 employees
Third Harmonic Bio has abandoned plans to take its chronic spontaneous urticaria (CSU) drug into phase 2, instead preparing to sell the asset while liquidating the business.
Disease Area: Gastrointestinal, Immune Diseases, Multiple, Respiratory Diseases
Drug Type: Small Molecule
May 8, 2025
Korro Bio
Layoffs
Cambridge, MA
51-200 employees
In a bid to keep its business afloat into 2027, Korro Bio is streamlining its operations, a move that will involve a 20% workforce reduction, the biotech announced Wednesday alongside its Q1 business report. The layoffs, which will cost Korro $1.2 million in one-time payments, will help the biotech advance its assets to “key value inflection points.” In particular, Korro aims to complete its ongoing Phase I/IIa REWRITE trial, which is testing its investigational RNA-editing oligonucleotide KRRO-110 in alpha-1 antitrypsin deficiency. The company expects to wrap up REWRITE in 2026.
Disease Area: Gastrointestinal, Metabolic Diseases, Multiple, Neurological Diseases, Rare Diseases
Drug Type: Biologic
May 8, 2025
Vanda Pharmaceuticals
Negative Outlook
Washington DC
201-500 employees
We anticipate that our results of operations will fluctuate for the foreseeable future due to several factors, including our and our partners’ ability to continue to successfully commercialize our products, including activities related to Fanapt® for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults which was approved in April 2024 and acquired rights to PONVORY® in the U.S. and Canada in December 2023, the impact of the Medicare Part D benefit redesign effective January 1, 2025 under the Inflation Reduction Act of 2022, any possible payments made or received pursuant to license agreements, progress of our research and development efforts, the timing and outcome of clinical trials and related possible regulatory approvals and the status of existing and future potential litigation involving our products and intellectual property.
Disease Area: Dermatology, Gastrointestinal, Multiple, Neurological Diseases, Psychiatry
Drug Type: Biologic, Small Molecule
May 7, 2025
NGM Bio
Layoffs
San Mateo County, CA
51-200 employees
NGM Bio is cutting 85 employees, according to a San Francisco WARN Notice from last week. The layoffs, which will affect staff at its San Mateo County location, will take effect on June 30. The workforce reduction affects 75% of the workforce, Fierce Biotech reported May 12
Disease Area: Gastrointestinal, Metabolic Diseases, Multiple, Oncology, Rare Diseases
Drug Type: Biologic
May 1, 2025
Ardelyx
Neutral Outlook
Waltham, MA
201-500 employees
While the impact of the IRA on the pharmaceutical industry cannot yet be fully determined, it is likely to be significant
Disease Area: Cardiology, Chronic Disease, Gastrointestinal, Metabolic Diseases, Multiple
Drug Type: Small Molecule
May 1, 2025
Bausch Health
Negative Outlook
Bridgewater, NJ
10,001-50,000 employees
These negotiations could, among other things, accelerate revenue erosion prior to the expiration of intellectual property protections. The effect of reducing prices and reimbursement for certain of our products could significantly impact our business and consolidated results of operations.
Disease Area: Dermatology, Gastrointestinal, Multiple, Neurological Diseases
Drug Type: Small Molecule